Radioimmunotherapy for breast cancer using indium-11 l/yttrium-90 BrE-3: Results of a phase i clinical trial

Journal of Nuclear Medicine

Volumn 38, Issue 8, 1997, Pages 1180-1185

  Denardo, Sally J ^a   Kramer, Elissa L ^a   O'Donnell, Robert T ^a   Richman, Carol M ^a   Salako, Qansy A ^a   Shen, Sui ^a   Noz, M ^a   Glenn, Stephan D ^a   Ceriani, Roberto L ^a   Denardo, Gerald L ^a  

^a Molecular Cancer Institute   (United States)

Author keywords

Bre 3; Breast cancer; Radioirnmunotherapy; Yttrium 90

Indexed keywords

INDIUM 111; MONOCLONAL ANTIBODY; PENTETATE INDIUM IN 111; YTTRIUM 90;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RADIOISOTOPE THERAPY; URTICARIA;

BREAST NEOPLASMS; CHELATING AGENTS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MIDDLE AGED; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 0030816178     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wingo PA, long T, Beiden S. Cancer statistics, 1995. ÇA Cancer J Clin 1995;45:832.
2. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992; 19:317-332.
3. Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994;21:19-24.
4. Bunn PA, Dienhart DG, Gonzalez R. Imaging, pharmacokinetics and antitumor effects of anti-breast cancer antibodies in mouse and man. In: Ceriani RL, ed. Breast epithelial antigens, New York: Plenum Press; 1991:227-232.
5. Ceriani RL, Peterson JA, Lamport D, Amiya R. Epitope expression on the breast epithelial mucin. Breast Cancer Res Treat 1992;24:103-113.
6. Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J Nucl Med 1993;34:1067-1074.
7. Ceriani RL, Peterson JA, Blank EW, Chan CM, Caileau R. Development and characterization of breast carcinoma cell lines as in vitro and in vivo for breast cancer diagnosis and therapy. In Vitro 1993;28A:221-235.
8. Howell LP, DeNardo SJ, Levy NB, DeNardo GL. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995;10:129-135.
9. Stemmer SM, Glenn S, Butchko G, Jones RB. High dose 90-Y MX-DTPA BrE3 and autologous hematopoietic stem cell support for the treatment of advanced breast cancer [J. In: Rosenberg SA, ed. The fifth conference of radioimmunodetection and radioimmunotherapy of cancer. Baltimore: Raven Press; 1994:54.
10. Lamki LM, Podoloff DA, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer, a Phase I study. J Nucl Med 1992; 32:1326-1332.
11. Ceriani RL, Sasaki M, Orthendahl D, Kaugman L. Localization of human breast tumors grafted in nude mice with a monoclonal antibody directed against a defined cell surface antigen of human mammary epithelial cells. Breast Cancer Res Treat 1988;12:177-189.
12. Ceriani RL, Blank EW, Petersen JA. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res 1987;47:532-540.
13. Ceriani RL, Blank EW. Experimental therapy of human breast tumors with 1-131labeled monoclonal antibodies prepared against HMFG. Cancer Res 1988;48:46644672.
14. Blank EW, Pant KD, Chan CM, Peterson JA, Ceriani RL. A novel anti-breast epithelial mucin MoAb (BrE-3). Cancer J 1992;5:38-44.
15. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL. Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by antibodies against the human milk fat globule. Hybridoma 1990;9:221-235.
16. Thomas SR, Maxon HR, Keriakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3:253-255.
17. Eary JF, Applebaum FL, Durack L, Brown P. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys 1989;16:382-387.
18. Macey DJ, DeNardo GL, DeNardo SJ. A treatment planning approach for radioimmunotherapy. In: Vaeth JM, Meyer JL, eds. Frontiers in radiation therapy and oncology. Basel: S. Karger; 1990:123-131.
19. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of 90-yttrium using a Weiner filter. Med Phys 1994;21:1409-1417.
20. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides: MIRD pamphlet no. 1. New York: Society of Nuclear Medicine; 1976.
21. Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 1979;6:307-308.
22. Snyder WS, Ford MR, Warner GG, Watson SB. Sabsorbed dose per unit cumulated activity for selected radionuclides and organs: MIRD pamphlet no. 11. New York: Society of Nuclear Medicine; 1975.
23. DeNardo GL, Mahe MA, DeNardo SJ, et al. Body and blood clearance and marrow radiation dose of 131I-Lym-l in patients with B-cell malignancies. Nucl Med Commun 1993;14:587-595.
24. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib Immunoconjug Radiopharm 1990;3:213-233.
25. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995;20: 117-125.
26. DeNardo GL, DeNardo SJ. Treatment of B-lymphocyte malignancies with 1311Lym-1 and 67Cu-2IT-BAT-Lym-l and opportunities for improvement. In: Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1994; 217-227.
27. Dillehay LE, Mayer R, Zhang YG, et al. Use of bremsstrahlung radiation to monitor 90Y tumor and whole body radiation in mice. Cancer 1994;73:945-950.
28. Couto JR, Blank EW, Kiwan R, Padlan EA, Ceriani RL. Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3. Adv Exp Med Biol 1994;353:55-59.
29. Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995;55(suppl):5916s5920s. 1: